Targeting a specific protein to improve treatment for ovarian cancer
Official title: Targeting EGFL6 in Ovarian Cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-11171048 · Data updated 2026-11-12
This study is looking at a protein called EGFL6 in high-grade serous ovarian cancer to see if new treatments that block this protein can help improve cancer therapies and slow down tumor growth, and patients may have the chance to participate in trials to test these promising new options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 19, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $204,372 |
| NIH project number | 3P50CA281701-02S2 |
| Project ID | NIH-11171048 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with high-grade serous ovarian cancer who may benefit from new therapeutic approaches.
✕Less likely to help
Patients with other types of ovarian cancer or those who are not eligible for experimental therapies may not receive benefits from this research.
What this research studies
This research focuses on high-grade serous ovarian cancer, the most aggressive form of ovarian cancer, which has high mortality rates. The study investigates the role of a protein called EGFL6, which is found in tumor blood vessels and is linked to a suppressive immune environment in tumors. By developing and testing new antibodies that block EGFL6, the research aims to enhance the effectiveness of cancer therapies and reduce the growth of tumors. Patients may be involved in trials to assess the safety and efficacy of these new treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for ovarian cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in targeting angiogenesis in cancer treatment, but this specific approach targeting EGFL6 is novel.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Sood, Anil K — University of Tx Md Anderson Can Ctr
- Study coordinator: Sood, Anil K
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.